IN A RECENT paper, the use of intravenous injections of histamine in 25 cases of acute ischemia of the brain was described.1 The present paper reports experiences in an additional 50 cases. A team of one neurologist (A. R. F.) and six internists treated the 50 patients in a general hospital as part of a large group practice. The minimum of selectivity was used to determine the limits of histamine therapy. Patients with gross cerebral hemorrhage, cerebral edema, intracranial neoplasm, and terminal cardiac failure were not included in this study.
METHOD OF EVALUATION OF THERAPY
In order to evaluate more critically the results of therapy, my colleagues and I have used a quantitative and qualitative system to designate the neurological dysfunction before and after histamine therapy. Each case is tabulated so that our standards of improvement can be compared with those of other investigators, without the semantic difficulties that